ACXP:NSD-Acurx Pharmaceuticals LLC (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.83

Change

+0.38 (+11.01)%

Market Cap

USD 0.04B

Volume

0.05M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ACXP Stock Forecast & Price:
Based on the Acurx Pharmaceuticals LLC stock forecasts from 1 analysts, the average analyst target price for Acurx Pharmaceuticals LLC is USD 0.00 over the next 12 months. Acurx Pharmaceuticals LLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Acurx Pharmaceuticals LLC is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Acurx Pharmaceuticals LLC’s stock price was USD 3.83. Acurx Pharmaceuticals LLC’s stock price has changed by +20.06% over the past week, +33.45% over the past month and -15.45% over the last year.

About Acurx Pharmaceuticals LLC (ACXP:NSD)

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical tr ...Read More

Company Website : https://www.acurxpharma.com

Address : 259 Liberty Avenue, Staten Island, NY, United States, 10305

Employees : 4

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 4.89

Short Ratio : 1.01

52 Week Low : 2.33

Shorted Shares : 23,138

200 Day Moving Average : 3.46

Shorted Shares Previous Month : 21,851

50 Day Moving Average : 3.10

Shares Held By Insiders : 21.50%

Short Percentage : 0.25%

Shares Held by Institutions : 3.08%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+16.80 (+2.25%)

 USD83.46B 192.56 12.35
VRTX Vertex Pharmaceuticals Inc

+5.77 (+1.85%)

 USD82.49B 25.21 17.39
MRNA Moderna Inc

+5.46 (+3.15%)

 USD67.59B 6.10 4.60
BNTX BioNTech SE

+1.01 (+0.62%)

 USD41.19B 3.97 1.87
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
GMAB Genmab AS

+0.43 (+0.95%)

 USD31.54B 37.65 3.71
ALNY Alnylam Pharmaceuticals Inc

+11.69 (+5.32%)

 USD27.02B N/A -29.83
SGEN Seagen Inc

+1.45 (+1.23%)

 USD22.73B 55.02 -38.32
BGNE BeiGene Ltd

+5.80 (+3.09%)

 USD21.81B N/A -8.80
ARGX argenx NV ADR

-1.17 (-0.30%)

 USD21.32B N/A -22.20

ETFs Containing ACXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.37% 82% B- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.37% 82% B- 61% D-
Trailing 12 Months  
Capital Gain -17.10% 82% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.10% 82% B- 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.71% 52% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.71% 52% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 16.00% 97% A+ 75% C
Risk Adjusted Return -60.66% 33% F 19% F
Market Capitalization 0.04B 31% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.92 27% F 22% F
Price / Cash Flow Ratio -8.86 76% C 70% C-
EV/EBITDA -3.11 72% C- 70% C-
Management Effectiveness  
Return on Equity -95.34% 32% F 18% F
Return on Invested Capital -168.85% 11% F 9% F
Return on Assets -55.23% 16% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.01 81% B- 72% C-
Short Percent 0.25% 92% A- 82% B-
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.